Cipher Pharmaceuticals Inc. (NASDAQ:CPHR) – Cormark lowered their Q1 2017 EPS estimates for shares of Cipher Pharmaceuticals in a research note issued on Monday. Cormark analyst D. Novak now forecasts that the firm will post earnings of $0.05 per share for the quarter, down from their prior estimate of $0.08. Cormark also issued estimates for Cipher Pharmaceuticals’ Q2 2017 earnings at $0.03 EPS, Q3 2017 earnings at $0.06 EPS, Q4 2017 earnings at $0.03 EPS and FY2017 earnings at $0.17 EPS.
Other research analysts have also issued reports about the company. TD Securities reiterated a “buy” rating and set a $7.50 price target on shares of Cipher Pharmaceuticals in a report on Saturday, August 13th. GMP Securities reiterated a “hold” rating on shares of Cipher Pharmaceuticals in a report on Saturday, August 13th. One analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $6.85.
Shares of Cipher Pharmaceuticals (NASDAQ:CPHR) opened at 3.879 on Tuesday. The company has a 50-day moving average of $4.03 and a 200 day moving average of $5.09. Cipher Pharmaceuticals has a 12-month low of $3.55 and a 12-month high of $6.37. The firm’s market cap is $101.61 million.
About Cipher Pharmaceuticals
Cipher Pharmaceuticals Inc is a specialty pharmaceutical dermatology company. The Company has a portfolio of commercial and late-stage products. It operates in the specialty pharmaceuticals segment. It acquires products and compounds for treatment of various medical needs. Its commercial product portfolio includes ABSORICA; SITAVIG; NUVAIL; BIONECT; CLN8; INOVA; PRO:12 MOUSSE; AL12; LOTION UMECTA; ACLARO; EPURIS; VANIQA; ACTIKERALL; BETEFLAM; LIPOFEN; CONZIP, and DURELA.
Receive News & Ratings for Cipher Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.